The course of influenza and its complications in the conditions of one hospital


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To analyze moderate and severe influenza cases in the clinical center in the 2018-2019 season and to generalize clinical manifestations, complications, and follow-up cases. Subjects and methods. The retrospective study enrolled 61 patients aged 18-95 years with a confirmed diagnosis of influenza. Influenza virus RNA was detected by a reverse transcription-polymerase chain reaction (PCR) assay. IFNL3 single nucleotide polymorphism (rs8099917 T/G) and IFNL4 (rs12979860 C/T) were determined by PCR using the certified Russian reagent kit. Results. The predominant influenza A (H1N1)pdm09 strain was detected in 97% of patients with typical clinical signs of the disease. The proportion of vaccinated patients was 9.8%. The main complication of influenza was community-acquired pneumonia (54%). The combination of the antiviral drugs oseltamivir and imidazolylidene pentandiol acid (IPA) did not increase the efficiency of treatment. Complaints persisted in a significant proportion of patients within 30 days following hospital discharge. There was a tendency towards more frequent detection of the IFNL4 rs12979860 TT genotype in patients with pneumonia. Conclusion. The disease had typical clinical presentations, with community-acquired pneumonia prevailing among the complications. No complications of influenza occurred in patients under 30 years of age and in vaccinated patients. Most patients had a long recovery period.

Full Text

Restricted Access

About the authors

Georgy V. Sapronov

Central Clinical Hospital with Polyclinic, Presidential Administration of the Russian Federation

Email: g_sapronov@mail.ru
Can. Med. Sci., Head, Infectious Diseases Unit Two Moscow, Russia

Veronika V. Dyachenko

Central Clinical Hospital with Polyclinic, Presidential Administration of the Russian Federation

Email: doctorvv@bk.ru
Infectiologist, Central Clinical Hospital with Polyclinic Moscow, Russia

Nadezhda G. Shevchenko

Central Clinical Hospital with Polyclinic, Presidential Administration of the Russian Federation

Email: dr.nadya@inbox.ru
Infectiologist Moscow, Russia

Natalia M. Glagoleva

Central Clinical Hospital with Polyclinic, Presidential Administration of the Russian Federation

Email: nglagoleva5@gmail.com
Can. Med. Sci., Head, Infectious Diseases Unit One Moscow, Russia

Svetlana V. Trushakova

Honored Academician N.F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health

Email: s.trushakova@gmail.com
Can. Biol. Sci., Senior Researcher, Laboratory of Influenza Etiology and Epidemiology Moscow, Russia

Kirill G. Krasnoslobodtsev

Honored Academician N.F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health

Email: kkg_87@mail.ru
Researcher, Laboratory of Influenza Etiology and Epidemiology Moscow, Russia

Lyudmila I. Nikolaeva

Honored Academician N.F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health

Email: l.i.nikolaeva@mail.ru
Biol.D, Head, Laboratory of Biological Agents Moscow, Russia

Elena I Burtseva

Honored Academician N.F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health

Email: elena-burtseva@yandex.ru
MD, Head, Laboratory of Biological Agents Moscow, Russia

References

  1. WHO. Influenza (Seasonal). Media centre: WHO, 6 November 2018. http://www.who.int/mediacentre/factsheets/fs211/en/
  2. Kilbourne E.D. Influenza pandemics of the 20th century. Emerg. Infect. Dis. 2006; 12(1): 9-14. https://doi.org/10.3201/ eid1201.051254
  3. WHO. Influenza (Seasonal). Media centre: WHO, 31 May 2018. https://www.who.int/ru/news-room/fact-sheets/detail/ influenza-(seasonal)
  4. Brades M., Klauschen F., Kuchen S., Germain R.N. A systems analysis identifies a feedforward inflammatory circuit leading to lethal influenza infection. Cell. 2013; 154(1): 197-212. https://doi.org/10.1016/j.cell.2013. 06.013
  5. Vidy A., Maisonnasse P., Da Costa B., Delmas B., Chevalier C., Le Goffic R. The influenza virus protein PB1-F2 increases viral pathogenesis through neutrophil recruitment and NK cells inhibition. PLoS One 2016; 11(10): e0165361. https://doi. org/10.1371/journal.pone.0165361
  6. Львов Д.К., Яшкулов К.Б., Прилипов А.Г., Бурцева Е.И., Щелканов М.Ю., Шляпникова О.В. и др. Обнаружение аминокислотных замен аспарагиновой кислоты на глицин и аспарагин в рецепторсвязывающем сайте гемагглютинина в вариантах пандемического вируса гриппа A/H1N1 от больных с летальным исходом и со среднетяжелой формой заболевания. Вопр. вирусол. 2010; 55(3): 15-28.
  7. ВОЗ. Информационный бюллетень. Январь 2019. Социальные аспекты здоровья населения (Электронный научный журнал) 2019; 65(1): 15
  8. Львов Д.К., Бурцева Е.И., Мукашева Е.А., Колобухина Л.В., Богданова В.С., Бовин Н.В. и др. Особенности циркуляции и свойств вирусов гриппа в эпидемическом сезоне 2018-2019 гг. в России и странах Северного полушария. Проблемы особо опасных инфекций. 2019; (3): 66-73. https://doi. org/10.21055/0370-1069-2019-3-66-74
  9. Чучалин А.Г., Сологуб Т.В., ред. Грипп у взрослых: методические рекомендации по диагностике, лечению, специфической и неспецифической профилактике. СПб; НП-Принт, 2014. 192 c
  10. Ющук Н.Д., Венгеров Ю.Я. Лекции по инфекционным болезням. B 2 т. 4-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2016
  11. Николаева Л.И., Сапронов Г.В., Куприянов В.В. Роль интерферонов-лямбда в иммунной защите от гриппа. Инфекционные болезни 2019; 17(1): 86-92. https://doi. org/10.20953/1729-9225-2019-1-86-92
  12. Keshavarz M., Namdari H., Farahmand M., Mehrbod P., Mokhtari-Azad T., Rezaei F. Association of polymorphisms in inflammatory cytokines encoding genes with severe cases of influenza A/H1N1 and B in an Iranian population. Virology J. 2019; 16: article number 79. https:// virologyj.biomedcentral. com/articles/10.1186/s12985-019-1187-8

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies